Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Biomerica (BMRA) over the last 16 years, with Q4 2025 value amounting to $2.5 million.

  • Biomerica's Cash & Equivalents rose 720.91% to $2.5 million in Q4 2025 from the same period last year, while for Nov 2025 it was $2.5 million, marking a year-over-year increase of 720.91%. This contributed to the annual value of $2.4 million for FY2025, which is 4247.0% down from last year.
  • According to the latest figures from Q4 2025, Biomerica's Cash & Equivalents is $2.5 million, which was up 720.91% from $3.1 million recorded in Q3 2025.
  • In the past 5 years, Biomerica's Cash & Equivalents registered a high of $10.2 million during Q1 2022, and its lowest value of $2.4 million during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $5.1 million, with a median of $5.0 million in 2021.
  • Per our database at Business Quant, Biomerica's Cash & Equivalents skyrocketed by 12044.97% in 2021 and then crashed by 6711.94% in 2023.
  • Quarter analysis of 5 years shows Biomerica's Cash & Equivalents stood at $7.2 million in 2021, then fell by 29.62% to $5.1 million in 2022, then soared by 40.79% to $7.1 million in 2023, then tumbled by 66.75% to $2.4 million in 2024, then grew by 7.21% to $2.5 million in 2025.
  • Its Cash & Equivalents stands at $2.5 million for Q4 2025, versus $3.1 million for Q3 2025 and $2.4 million for Q2 2025.